(¿Â¶óÀÎ) 2022³â Á¦5Â÷ ³»°úºÐ°úÀü¹®ÀÇ ¿¬¼ö±³À° : 2022-06-04±³À°ÀÏÀÚ : 2022-06-04
±³À°Àå¼Ò : ¿Â¶óÀÎ ±³À°
±³À°ÁÖÁ¦ :
(¿Â¶óÀÎ) 2022³â Á¦5Â÷ ³»°úºÐ°úÀü¹®ÀÇ ¿¬¼ö±³À°ÁÖÃÖ±â°ü : ´ëÇѳ»°úÇÐȸ
´ã´çÀÚ : ´ëÇѳ»°úÇÐȸ
¿¬¶ôó : 02-793-4364
À̸ÞÀÏ :
kaim4364@kaim.or.kr ±³À°Á¾·ù : ³»°ú
Âü¼®¿¹»óÀοø : 1500¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 31 ½Ã°£ 0ºÐ
¼¼ºÎ¼ö°·á : 80,000¿ø
ºñ°í »çÀüµî·Ï: (³»°úÀü°øÀÇ¡¤Àü¹®ÀÇ) 50,000¿ø / (Ÿ°ú/ºñȸ¿ø) 70,000¿ø / ´çÀϵî·Ï: (³»°úÀü°øÀÇ¡¤Àü¹®ÀÇ) 60,000¿ø / (Ÿ°ú/ºñȸ¿ø) 80,000¿ø
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 06-04 ¿Â¶óÀÎ 08:30~09:00 Frontline Treatment for Multiple Myeloma ±èÁø¼®(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 06-04 ¿Â¶óÀÎ 09:00~09:30 Optimal Treatment Strategy for PTCL ¾ç´öȯ(Àü³²ÀÇ´ë)
±³À°½Ã°£ 06-04 ¿Â¶óÀÎ 09:30~10:00 Frontline Treatment for MDS ¹®¿µÃ¶(ÀÌÈÀÇ´ë)
±âŸ 06-04 ¿Â¶óÀÎ 10:00~10:05 ºÐ°úÀüÀÓÀÇ ¼ö·Ã±â·Ï µî °øÁö À̹οµ(¼øõÇâÀÇ´ë)
±³À°½Ã°£ 06-04 ¿Â¶óÀÎ 10:30~11:00 Head & Neck Cancer À̼¼ÈÆ(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 06-04 ¿Â¶óÀÎ 11:00~11:30 Biliary & Pancreas Cancer ±èÁø¿ø(¼¿ïÀÇ´ë)
±³À°½Ã°£ 06-04 ¿Â¶óÀÎ 11:30~12:00 Management of Immunotherapy Related Toxicities °í¼¼ÀÏ(°æ»óÀÇ´ë)
±³À°½Ã°£ 06-04 ¿Â¶óÀÎ 12:00~12:30 Immunizations in Adults with Cancer ÀÌÀºÁ¤(¼øõÇâÀÇ´ë)
±³À°½Ã°£ 06-04 ¿Â¶óÀÎ 08:30~08:55 Acute coronary syndrome¿¡¼ »õ·Î¿î P2Y12 ¾ïÁ¦Á¦ÀÇ ¿ªÇÒ È«¿µÁØ(Àü³²ÀÇ´ë)
Åä·Ð 06-04 ¿Â¶óÀÎ 08:55~09:00 Q&A È«¿µÁØ(Àü³²ÀÇ´ë)
±³À°½Ã°£ 06-04 ¿Â¶óÀÎ 09:00~09:25 ÀÌ»óÁöÁúÇ÷Áõ ȯÀÚ¿¡¼ PCSK9¾ïÁ¦Á¦ÀÇ ¿ªÇÒ ±èº´Áø(¼º±Õ°üÀÇ´ë)
Åä·Ð 06-04 ¿Â¶óÀÎ 09:25~09:30 Q&A ±èº´Áø(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 06-04 ¿Â¶óÀÎ 09:30~09:55 ½É¹æ¼¼µ¿ ºñ¾à¹° ¸®µëÁ¶Àý¹ý ÃֽŠÁö°ß (Cryoablation µî) ±èÁø¼®(°í·ÁÀÇ´ë)
Åä·Ð 06-04 ¿Â¶óÀÎ 09:55~10:00 Q&A ±èÁø¼®(°í·ÁÀÇ´ë)
±âŸ 06-04 ¿Â¶óÀÎ 10:00~10:05 ºÐ°úÀüÀÓÀÇ ¼ö·Ã±â·Ï µî °øÁö ³ªÁø¿À(°í·ÁÀÇ´ë)
±³À°½Ã°£ 06-04 ¿Â¶óÀÎ 10:30~10:55 Updated International and Korean Hypertension Guidelines – Review of Current Recommendations ÃÖ¼ºÈÆ(ÇѸ²ÀÇ´ë)
Åä·Ð 06-04 ¿Â¶óÀÎ 10:55~11:00 Q&A ÃÖ¼ºÈÆ(ÇѸ²ÀÇ´ë)
±³À°½Ã°£ 06-04 ¿Â¶óÀÎ 11:00~11:25 Recent Update of Aortic Stenosis Trial and Management ÃÖö¿õ(°í·ÁÀÇ´ë)
Åä·Ð 06-04 ¿Â¶óÀÎ 11:25~11:30 Q&A ÃÖö¿õ(°í·ÁÀÇ´ë)
±³À°½Ã°£ 06-04 ¿Â¶óÀÎ 11:30~11:55 Recent Update on Heart Failure Guidelines - What ±èÀÎö(°è¸íÀÇ´ë)
Åä·Ð 06-04 ¿Â¶óÀÎ 11:55~12:00 Q&A ±èÀÎö(°è¸íÀÇ´ë)
±³À°½Ã°£ 06-04 ¿Â¶óÀÎ 12:00~12:25 Updates in Cardiac Implantable Electronic Devices ¿ÀÀÏ¿µ(¼¿ïÀÇ´ë)
Åä·Ð 06-04 ¿Â¶óÀÎ 12:25~12:30 Q&A ¿ÀÀÏ¿µ(¼¿ïÀÇ´ë)
±³À°½Ã°£ 06-04 ¿Â¶óÀÎ 08:30~09:15 Asthma-COPD Overlap in Korea ¹Ý°¡¿µ(ÇѸ²ÀÇ´ë)
±³À°½Ã°£ 06-04 ¿Â¶óÀÎ 09:15~10:00 How to Step Down in Patients with Well-Controlled Asthma? ±è¼öÁ¤(°æºÏÀÇ´ë)
±âŸ 06-04 ¿Â¶óÀÎ 10:00~10:05 ºÐ°úÀüÀÓÀÇ ¼ö·Ã±â·Ï µî °øÁö ÀÌ»ó¹Î(°¡ÃµÀÇ´ë)
±³À°½Ã°£ 06-04 ¿Â¶óÀÎ 10:30~11:10 Practical Diagnostic Approach to Drug Allergy ÃÖ±æ¼ø(°í½ÅÀÇ´ë)
±³À°½Ã°£ 06-04 ¿Â¶óÀÎ 11:10~11:50 HLA Allele and Drug Hypersensitivity ¹Ú¼Ò¿µ(Áß¾ÓÀÇ´ë)
±³À°½Ã°£ 06-04 ¿Â¶óÀÎ 11:50~12:30 Hypersensitivity Reaction to COVID-19 Vaccine ÀÌ¿ë¿ø(°üµ¿ÀÇ´ë)
±³À°½Ã°£ 06-04 ¿Â¶óÀÎ 08:30~09:00 Novel Treatments in Systemic Lupus Erythematosus °û½Â±â(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 06-04 ¿Â¶óÀÎ 09:00~09:30 Interstitial Lung Disease Assoicated with Rheumatic Diseases ±èÇö¼÷(¼øõÇâÀÇ´ë)
±³À°½Ã°£ 06-04 ¿Â¶óÀÎ 09:30~10:00 Large Vessel Vasculitis : Updated Treatment Guideline ÃÖÂù¹ü(ÇѾçÀÇ´ë)
±âŸ 06-04 ¿Â¶óÀÎ 10:00~10:05 ºÐ°úÀüÀÓÀÇ ¼ö·Ã±â·Ï µî °øÁö ±è±ÙÅÂ(°í½ÅÀÇ´ë)
±³À°½Ã°£ 06-04 ¿Â¶óÀÎ 10:30~11:00 Scleromyxedema with Multiple Systemic Involvement: A Case Report ÀÌ°æ¾ð(¼øõÇâÀÇ´ë)
±³À°½Ã°£ 06-04 ¿Â¶óÀÎ 11:00~11:30 Development of Peripheral Spondyloarthritis after COVID-19 in The HLA-B27-Positive Monozygotic Twins: With A Single Cell Tranome Profiling ±èÁ¤°ï(ÀÎÁ¦ÀÇ´ë)
±³À°½Ã°£ 06-04 ¿Â¶óÀÎ 11:30~12:00 A Patient with Late-on Limb-Girdle Muscular Dystrophy Type 2B Mimicking Dermatomyositis: A Case Report and Review ±è¹ÎÁ¤(¼¿ïÀÇ´ë)
±³À°½Ã°£ 06-04 ¿Â¶óÀÎ 12:00~12:30 Transient Systemic Lupus Erythematosus-like Syndrome Associated With Parvovirus B19 Infection: A Case Report ±è¹®¿µ(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 06-04 ¿Â¶óÀÎ 08:30~09:00 Update in Approach to Patients with Diabetes Insipidus ±èÇý¼ø(°è¸íÀÇ´ë)
±³À°½Ã°£ 06-04 ¿Â¶óÀÎ 09:00~09:30 Medical Management of Hyperprolactinemia ÇÏÁ¤ÈÆ(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 06-04 ¿Â¶óÀÎ 09:30~10:00 Medical Management of Cushing¡¯s Disease ±¸Ã¶·æ(¿¬¼¼ÀÇ´ë)
±âŸ 06-04 ¿Â¶óÀÎ 10:00~10:05 ºÐ°úÀüÀÓÀÇ ¼ö·Ã±â·Ï µî °øÁö ±è¼ö°æ(Â÷ÀÇ°úÇдëÇÐ)
±³À°½Ã°£ 06-04 ¿Â¶óÀÎ 10:30~11:00 Management of Thyroid Nodules with AUS/FLUS Results ½Åµ¿¿±(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 06-04 ¿Â¶óÀÎ 11:00~11:30 Management of Low- to Intermediate Risk Thyroid Cancer ¹Ú¿µÁÖ(¼¿ïÀÇ´ë)
±³À°½Ã°£ 06-04 ¿Â¶óÀÎ 11:30~12:00 Practical Points of RAI Treatment Cancer and Graves Disease ±è¹ÎÈñ(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 06-04 ¿Â¶óÀÎ 12:00~12:30 When and How to Treat Subclinical Thyroid Dysfunction À¯¿ø»ó(´Ü±¹ÀÇ´ë)
±³À°½Ã°£ 06-04 ¿Â¶óÀÎ 13:30~13:55 Differential Diagnosis of Ascites Á¶ÁÖ¿¬(Á¶¼±ÀÇ´ë)
±³À°½Ã°£ 06-04 ¿Â¶óÀÎ 13:55~14:15 Recent Update on the Management of Chronic Hepatitis C °¹Î±Ô(¿µ³²ÀÇ´ë)
±³À°½Ã°£ 06-04 ¿Â¶óÀÎ 14:15~14:40 Diagnosis and Management of Cholangiocarcinoma Á¶Àº¾Ö(Àü³²ÀÇ´ë)
±³À°½Ã°£ 06-04 ¿Â¶óÀÎ 14:40~15:00 Diagnosis and Management of Chronic Pancreatitis ÀÌÅÂÀ±(°Ç±¹ÀÇ´ë)
±âŸ 06-04 ¿Â¶óÀÎ 15:00~15:05 ºÐ°úÀüÀÓÀÇ ¼ö·Ã±â·Ï µî °øÁö ÀÌÇö¿õ(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 06-04 ¿Â¶óÀÎ 15:30~16:00 Recent Advances on Gastric Subepithelial Tumor ±èµµÈÆ(¿ï»êÀÇ´ë)
±³À°½Ã°£ 06-04 ¿Â¶óÀÎ 16:00~16:30 Diagnosis and Management of Peptic Ulcer Disease ¼½ÂÀÎ(ÇѸ²ÀÇ´ë)
±³À°½Ã°£ 06-04 ¿Â¶óÀÎ 16:30~17:00 Colonoscopy: Quality Indicators °û¹Î¼·(°æÈñÀÇ´ë)
±³À°½Ã°£ 06-04 ¿Â¶óÀÎ 17:00~17:30 Diagnosis and Management of Chronic Diarrhea ±è¿ë¼º(¿ø±¤ÀÇ´ë)
±³À°½Ã°£ 06-04 ¿Â¶óÀÎ 13:30~14:15 Preventing Transmission of Multidrug Resistant Gram-Negatives in Hospitalised Patients ±èŹ(¼øõÇâÀÇ´ë)
±³À°½Ã°£ 06-04 ¿Â¶óÀÎ 14:15~15:00 Innovative Uses of MALDI-TOF and Other Rapid Diagnositc Tests in the Clinical Microbiology Lab ¹ÚÁ¤¼ö(¼¿ïÀÇ´ë)
±âŸ 06-04 ¿Â¶óÀÎ 15:00~15:05 ºÐ°úÀüÀÓÀÇ ¼ö·Ã±â·Ï µî °øÁö ±èÃæÁ¾(ÀÌÈÀÇ´ë)
±³À°½Ã°£ 06-04 ¿Â¶óÀÎ 15:30~16:10 Clostridioides Difficile 2021 Focused Update À±¿µ°æ(°í·ÁÀÇ´ë)
±³À°½Ã°£ 06-04 ¿Â¶óÀÎ 16:10~16:50 IDSA Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections °Ã¶ÀÎ(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 06-04 ¿Â¶óÀÎ 16:50~17:30 Vancomycin ¼Û°æÈ£(¼¿ïÀÇ´ë)
±³À°½Ã°£ 06-04 ¿Â¶óÀÎ 13:30~13:55 Update in the pathogenesis and Tx of IgAN Á¤°æȯ(°æÈñÀÇ´ë)
Åä·Ð 06-04 ¿Â¶óÀÎ 13:55~14:00 Q&A Á¤°æȯ(°æÈñÀÇ´ë)
±³À°½Ã°£ 06-04 ¿Â¶óÀÎ 14:00~14:25 Update in the treatment of MCD and FSGS ¹ÝÅÂÇö(°¡Å縯ÀÇ´ë)
Åä·Ð 06-04 ¿Â¶óÀÎ 14:25~14:30 Q&A ¹ÝÅÂÇö(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 06-04 ¿Â¶óÀÎ 14:30~14:55 Diagnosis and treatment of MPGN À̹ÌÁ¤(Â÷ÀÇ°úÇдëÇÐ)
Åä·Ð 06-04 ¿Â¶óÀÎ 14:55~15:00 Q&A À̹ÌÁ¤(Â÷ÀÇ°úÇдëÇÐ)
±³À°½Ã°£ 06-04 ¿Â¶óÀÎ 15:00~15:25 Anti-podocyte antibody and MGN ÃÖÈÆ¿µ(¿¬¼¼ÀÇ´ë)
Åä·Ð 06-04 ¿Â¶óÀÎ 15:25~15:30 Q&A ÃÖÈÆ¿µ(¿¬¼¼ÀÇ´ë)
±âŸ 06-04 ¿Â¶óÀÎ 15:30~15:35 ºÐ°úÀüÀÓÀÇ ¼ö·Ã±â·Ï µî °øÁö ¹®ÁÖ¿µ(°æÈñÀÇ´ë)
±³À°½Ã°£ 06-04 ¿Â¶óÀÎ 16:00~16:25 Atypical HUS ÀÌÁ¤Ç¥(¼¿ïÀÇ´ë)
Åä·Ð 06-04 ¿Â¶óÀÎ 16:25~16:30 Q&A ÀÌÁ¤Ç¥(¼¿ïÀÇ´ë)
±³À°½Ã°£ 06-04 ¿Â¶óÀÎ 16:30~16:55 Lupus Nephritis Â÷ÁøÁÖ(°í·ÁÀÇ´ë)
Åä·Ð 06-04 ¿Â¶óÀÎ 16:55~17:00 Q&A Â÷ÁøÁÖ(°í·ÁÀÇ´ë)
±³À°½Ã°£ 06-04 ¿Â¶óÀÎ 17:00~17:25 ANCA-associated GN ±è±âÇ¥(ÀÎÇÏÀÇ´ë)
Åä·Ð 06-04 ¿Â¶óÀÎ 17:25~17:30 Q&A ±è±âÇ¥(ÀÎÇÏÀÇ´ë)
±³À°½Ã°£ 06-04 ¿Â¶óÀÎ 13:30~14:00 PreCOPD & COPD: Early Diagnosis & Treatment Ȳ¿ëÀÏ(ÇѸ²ÀÇ´ë)
±³À°½Ã°£ 06-04 ¿Â¶óÀÎ 14:00~14:30 Update on the Role of Inhaled Corticosteroids in Chronic Airway Diseases ³ª½Â¿ø(¿ï»êÀÇ´ë)
±³À°½Ã°£ 06-04 ¿Â¶óÀÎ 14:30~15:00 Update on the Biologics in Chronic Airway Diseases ¹®Áö¿ë(ÇѾçÀÇ´ë)
±âŸ 06-04 ¿Â¶óÀÎ 15:00~15:05 ºÐ°úÀüÀÓÀÇ ¼ö·Ã±â·Ï µî °øÁö ¹Ú¿ë¹ü(ÇѸ²ÀÇ´ë)
±³À°½Ã°£ 06-04 ¿Â¶óÀÎ 15:30~16:00 Update on the Treatment of ARDS ±è¿ø¿µ(Áß¾ÓÀÇ´ë)
±³À°½Ã°£ 06-04 ¿Â¶óÀÎ 16:00~16:30 Management of Severe COVID-19 Patients & Post-Discharge Care ±èÁÖÇý(±¹¸³Áß¾ÓÀÇ·á¿ø)
±³À°½Ã°£ 06-04 ¿Â¶óÀÎ 16:30~17:00 Update on the Critical Care Procedures Á¶¿ìÇö(ºÎ»êÀÇ´ë)